News | December 27, 2022
Hetero's COVID-19 oral drug gets WHO prequalification
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
More women centric initiatives being the need of the hour for holistic development
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Subscribe To Our Newsletter & Stay Updated
